{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:29:54Z","timestamp":1774016994788,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Regulatory agencies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, and the Japanese Pharmaceutical and Medical Device Agency (PMDA) provide scientific and public health guidance with cardiac safety being paramount in drug development of new investigational products (IP). Cardiac safety is not a singular undertaking but rather encompasses many elements to be considered beyond measurement of the QT interval before a candidate drug receives regulatory approval. These safety assessments may include evaluation of additional targeted and non\u2010targeted cardiovascular effects such as whether the IP mediates cardiac or pericardial inflammation or affects blood pressure, the coronary or systemic vasculature, heart valves, or cardiac muscle. Historically, the primary cardiac safety concern of regulators was the proarrhythmic risk of new chemical entities and has been centered on the QT interval as a marker of a drug's ability to delay ventricular repolarization and its potential to precipitate lethal ventricular rhythms. Beyond this biomarker, there has only been tangential focus on the PR and QRS intervals, conduction disturbances and supraventricular arrhythmias, and formal regulatory guidance pertaining to these findings has not been published. Hence, this review is designed to expand the myopic view of cardiac safety beyond the QT interval and highlight the importance of clinical nonlethal arrhythmias and conduction abnormalities involving novel non\u2010antiarrhythmic small molecules for which more robust monitoring and surveillance should be contemplated.<\/jats:p>","DOI":"10.1111\/cts.70510","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:15:35Z","timestamp":1773198935000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["QT Myopia and Cardiac Safety: Expanding the Aperture of Arrhythmia Assessment in Early Phase Drug Development"],"prefix":"10.1111","volume":"19","author":[{"given":"Robert M.","family":"Lester","sequence":"first","affiliation":[{"name":"Celerion Inc.  Tempe Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Clark","sequence":"additional","affiliation":[{"name":"Celerion Inc.  Tempe Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-942X","authenticated-orcid":false,"given":"Sabina","family":"Paglialunga","sequence":"additional","affiliation":[{"name":"Celerion Inc.  Tempe Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061324"},{"key":"e_1_2_12_3_1","unstructured":"ICH \u201cThe Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non\u2010Antiarrhythmic Drugs E14 \u201dInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) https:\/\/database.ich.org\/sites\/default\/files\/E14_Guideline.pdf."},{"key":"e_1_2_12_4_1","unstructured":"FDA \u201cGuidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals \u201dFood and Drug Administration (2005) https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm074963.pdf."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70098"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026787"},{"key":"e_1_2_12_7_1","unstructured":"Administration USFD \u201cLamictal (Lamotrigine): Drug Safety Communication\u2014Studies Show Increased Risk of Heart Rhythm Problems in Patients With Heart Disease \u201dU.S. Food & Drug Administration (2021) https:\/\/www.fda.gov\/safety\/medical\u2010product\u2010safety\u2010information\/lamictal\u2010lamotrigine\u2010drug\u2010safety\u2010communication\u2010studies\u2010show\u2010increased\u2010risk\u2010heart\u2010rhythm\u2010problems."},{"key":"e_1_2_12_8_1","unstructured":"Administration USFD \u201cFDA Drug Safety Communication: Abnormal Heart Rhythms Associated With Use of Anzemet (Dolasetron Mesylate) \u201dU.S Food & Drug Administration (2010) https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010drug\u2010safety\u2010communication\u2010abnormal\u2010heart\u2010rhythms\u2010associated\u2010use\u2010anzemet\u2010dolasetron\u2010mesylate#:~:text=The%20FDA%20has%20informed%20patients%20and%20healthcare or%20rhythm%20problems%20*%20Congenital%20long%2DQT%20syndrome."},{"key":"e_1_2_12_9_1","unstructured":"ICH \u201cICH E14\/S7B Implementation Working Group Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential Questions and Answers \u201dInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2022) https:\/\/database.ich.org\/sites\/default\/files\/E14\u2010S7B_QAs_Step4_2022_0221.pdf."},{"key":"e_1_2_12_10_1","unstructured":"ICH \u201cICH E14\/S7B Questions and Answers: Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential \u2010 Training Materials \u201d(2022) https:\/\/database.ich.org\/sites\/default\/files\/ICH_E14\u2010S7B_TrainingMaterial_2022_0407.pdf."},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000905"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3284"},{"key":"e_1_2_12_13_1","unstructured":"CiPA \u201cCritical Discussion \u2010 Future of the Assessment of Drug\u2010Induced Arrhythmias and the Comprehensive In\u00a0Vitro Proarrhythmia Assay (CiPA) \u201dinThink Tank. Cardiac Safety Research Consortium presented at Cardiac Safety Research Consortium (2016) http:\/\/cardiac\u2010safety.org\/2016\/12\/critical\u2010discussion\u2010future\u2010of\u2010the\u2010assessment\u2010of\u2010drug\u2010induced\u2010arrhythmias\u2010and\u2010the\u2010comprehensive\u2010in\u2010vitro\u2010proarrhythmia\u2010assay\u2010cipa\/."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00017.2023"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3283"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.01.011"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.10.043"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.15.23290016"},{"key":"e_1_2_12_19_1","unstructured":"ICH \u201cE14 Clinical Evaluation of QT\/QTc Interval Prolongation for Non\u2010Antiarrhythmic Drugs \u2013 Questions and Answers (R3) Guidance for Industry \u201dInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2017) https:\/\/www.fda.gov\/ucm\/groups\/fdagov\u2010public\/@fdagov\u2010drugs\u2010gen\/documents\/document\/ucm073161.pdf."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.108.789081"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476\u20105381.2011.01433.x"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13940"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd12080285"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241201"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/s25092848"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.853614"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/SVIN.123.001126"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102133"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2023.2799"},{"key":"e_1_2_12_30_1","unstructured":"Food and Drug Administration \u201cCardioTag 510(k) Premarket Notification \u201d(2025) https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf24\/K243566.pdf."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.322389"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.679"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2193"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70145"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.3398"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.2c00822"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3585"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3660"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70510","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:38:10Z","timestamp":1774010290000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/cts.70510"],"URL":"https:\/\/doi.org\/10.1111\/cts.70510","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70510"}}